Volpara expands distro deal with GE Healthcare

Volpara Solutions said yesterday that it expanded its distribution agreement with GE Healthcare (NYSE:GE) to include the global distribution of its VolparaDensity software. Wellington, New Zealand-based Volpara said that its VolparaDensity software is designed to analyze mammograms using machine learning to provide automated, objective and volumetric breast density assessments and a breast density category that correlates to BI-RADS 5th and 5th editions. “There are still certain signs of breast cancer that are best seen on a mammogram, which is why the Invenia ABUS is used in addition to mammography. ABUS screening helps find cancers hiding in dense tissue. Accurate density measurements and quality imaging are very important in breast cancer detection. I encourage women to learn their breast density, understand their risk, and talk to their healthcare providers to get the personalized healthcare they need,” Dr. Joseph Russo of St. Luke’s University Health Network said in prepared remarks. Volpara touted that the system has been the subject of more than 100 peer-reviewed papers and 250 publications, and said that it is currently “We are excited to expand access to VolparaDensity as part of our product portfolio. Now, our customers outside the US will also have access to a proven technology that will help them identify women who may benefit from a supplemental screening modality, such as the Invenia ABUS,” GE Healthcare automated breast ultrasound...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Distribution Imaging Software / IT Women's Health GE Healthcare Volpara Solutions Source Type: news